Aspen Neuroscience filed for an initial public offering.
The company did not say how many shares it would list or at what price, according to a Friday filing with the Securities and Exchange Commission.
The clinical-stage biotechnology company said it plans to use proceeds from the IPO in part to fund the development of its lead product candidate, a potential cell therapy treatment for Parkinson's disease called sasineprocel.
The company applied to list shares on the Nasdaq Global Select Market under the symbol ASPE.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.